138 related articles for article (PubMed ID: 24344018)
21. Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.
Kim Y; Shiba-Ishii A; Nakagawa T; Husni RE; Sakashita S; Takeuchi T; Noguchi M
Pathol Int; 2017 Jun; 67(6):292-301. PubMed ID: 28544031
[TBL] [Abstract][Full Text] [Related]
22. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
Inal A; Kaplan MA; Kucukoner M; Urakcı Z; Kılınc F; Isıkdogan A
Rev Port Pneumol; 2014; 20(2):62-8. PubMed ID: 24210228
[TBL] [Abstract][Full Text] [Related]
23. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
24. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
25. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy.
Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP
J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.
Imai H; Kaira K; Mori K; Ono A; Akamatsu H; Matsumoto S; Taira T; Kenmotsu H; Harada H; Naito T; Murakami H; Endo M; Nakajima T; Yamada M; Takahashi T
BMC Cancer; 2015 Dec; 15():989. PubMed ID: 26690494
[TBL] [Abstract][Full Text] [Related]
27. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.
Cheng T; Dai X; Zhou DL; Lv Y; Miao LY
Med Oncol; 2015 Jan; 32(1):407. PubMed ID: 25465061
[TBL] [Abstract][Full Text] [Related]
28. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
29. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients.
Ferreira CG; van der Valk P; Span SW; Ludwig I; Smit EF; Kruyt FA; Pinedo HM; van Tinteren H; Giaccone G
Clin Cancer Res; 2001 Aug; 7(8):2468-74. PubMed ID: 11489828
[TBL] [Abstract][Full Text] [Related]
30. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
31. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
[TBL] [Abstract][Full Text] [Related]
32. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.
Zhao W; Yang Z; Liu X; Tian Q; Lv Y; Liang Y; Li C; Gao X; Chen L
J Int Med Res; 2013 Jun; 41(3):573-83. PubMed ID: 23613495
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy.
Koh YW; Lee HW
Medicine (Baltimore); 2017 May; 96(19):e6848. PubMed ID: 28489774
[TBL] [Abstract][Full Text] [Related]
34. Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen.
Zhao J; Zhao M; Jin B; Yu P; Hu X; Teng Y; Zhang J; Luo Y; Zhang L; Zheng S; Zhou Q; Li H; Liu Y; Qu X
BMC Cancer; 2012 Aug; 12():330. PubMed ID: 22852778
[TBL] [Abstract][Full Text] [Related]
35. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
36. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
[TBL] [Abstract][Full Text] [Related]
39. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
